API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and China.
Lead Product(s): Ifebemtinib,Cobimetinib
Therapeutic Area: Oncology Product Name: BI 853520
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hyfinity Investments
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 09, 2022
Details:
MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells.
Lead Product(s): MVR-T3011,Cobimetinib
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 19, 2022
Details:
The ongoing Phase 1b/2 RMC-4630-02 trial is designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of RMC-4630 and cobimetinib in adult patients with relapsed/refractory solid tumors that harbor specific genomic mutations.
Lead Product(s): Vociprotafib,Cobimetinib
Therapeutic Area: Oncology Product Name: RMC-4630
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.
Lead Product(s): Ifebemtinib,Cobimetinib
Therapeutic Area: Oncology Product Name: BI 853520
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ennovation Ventures
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 03, 2020
Details:
The combination of KRAS G12C inhibitors and IN10018 induced FAK signaling by KRAS G12C inhibition, serving as one predominant mechanism of drug resistance of KRAS G12C inhibition, and IN10018 significantly decreases the FAK signaling induced by KRAS G12C inhibition.
Lead Product(s): Ifebemtinib,Cobimetinib
Therapeutic Area: Oncology Product Name: IN10018
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug .
Lead Product(s): Vociprotafib,Cobimetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2020
Details:
In a phase 3 study presented at the American Association for Cancer Research meeting, adding Tecentriq to the targeted melanoma drugs lowered the risk of disease progression.
Lead Product(s): Atezolizumab,Cobimetinib,Vemurafenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
The trial will include 6 study sites in the U. S and 3 study sites in Australia, and evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy with Roche's Cobimetinib.
Lead Product(s): Ifebemtinib,Cobimetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2020